In TNBC, a novel engineered nanoparticle (P-ACD24/CEL + P/shMFN1) synergistically elicits an anti-tumor immune response by blocking CD24, inducing tumor cell apoptosis, and reversing the M2-TAMs phenotype, thereby achieving the effect of combined immunotherapy (Zhao et al., 2023). The gene discussed is CD24; the disease is neoplasm.